Pancreaticoduodenal resection for primary unresectable pancreatic head cancer after neoadjuvant chemotherapy

The paper describes a clinical case of successful combined modality treatment of a patient with pancreatic ductal adenocarcinoma with extension to the superior mesenteric artery and vein. The examination revealed an unresectable tumor. Twelve courses of FOLFIRINOX therapy showed good results, upon which the treatment plan was changed and a typical pancreaticoduodenal resection was performed. Pathological examination revealed ductal adenocarcinoma urT1N0M0R0, TRG 2. The postoperative period was uneventful. The efficacy of drug treatment for ductal adenocarcinoma has increased markedly in recent years. Neoadjuvant chemotherapy can be considered the most effective for locally advanced tumors.

1. Oba A., Ho F., Bao Q.R., Al-Musawi M.H., Schulick R.D., DelChiaro M. Neoadjuvant treatment in pancreatic cancer. Front. Oncol. 2020; 10: 245. https://doi.org/10.3389/fonc.2020.00245

2. Tempero M.A., Malafa M.P., Al-Hawary M., Behrman S.W., Benson A.B., Cardin D.B., Chiorean E.G., Chung V., Czito B., DelChiaro M., Dillhoff M., Donahue T.R., Dotan E., Ferrone C.R., Fountzilas C., Hardacre J., Hawkins W.G., Klute K., Ko A.H., Kunstman J.W., Lo Conte N., Lowy A.M., Moravek C., Nakakura E.K., Narang A.K., Obando J., Polanco P.M., Reddy S., Reyngold M., Scaife C., Shen J., Vollmer C., Wolff R.A., Wolpin B.M., Lynn B., George G.V. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021; 19 (4): 439–457. https://doi.org/10.6004/jnccn.2021.0017

3. Wright G.P., Poruk K.E., Zenati M.S., Steve J., Bahary N., Hogg M.E., Zuriekat A.H., Wolfgang C.L., Zeh H.J., Weiss M.J. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J. Gastrointest. Surg. 2016; 20 (11): 1830–1835. https://doi.org/10.1007/s11605-016-3256-2

4. Crippa S., Bittoni A., Sebastiani E., Partelli S., Zanon S., Lanese A., Andrikou K., Muffatti F., Balzano G., Reni M., Cascinu S., Falconi M. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur. J. Surg. Oncol. 2016; 42 (10): 1533–1539. https://doi.org/10.1016/j.ejso.2016.06.398

5. Zurleni T., Gjoni E., Altomare M., Rausei S. Conversion surgery for gastric cancer patients: a review. World J. Gastrointest. Oncol. 2018; 10 (11): 398–409. https://doi.org/10.4251/wjgo.v10.i11.398

6. Zhang B., Zhou F., Hong J., Ng D.M., Yang T., Zhou X., Jin J., Zhou F., Chen P., Xu Y. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. World J. Surg. Oncol. 2021; 19 (1): 182. https://doi.org/10.1186/s12957-021-02291-6

7. Gillen S., Schuster T., Meyer Zum Büschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7 (4): e1000267. https://doi.org/10.1371/journal.pmed.1000267

8. Suker M., Beumer B.R., Sadot E., Marthey L., Faris J.E., Mellon E.A., El-Rayes B.F., Wang-Gillam A., Lacy J., Hosein P.J., Moorcraft S.Y., Conroy T., Hohla F., Allen P., Taieb J., Hong T.S., Shridhar R., Chau I., Van Eijck C.H., Koerkamp B.G. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016; 17 (6): 801–810. https://doi.org/10.1016/S1470-2045(16)00172-8

9. Zhou Y., Liao S., You J., Wu H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Updates Surg. 2022; 74 (1): 43–53. https://doi.org/10.1007/s13304-021-01089-1

10. Cassinotto C., Cortade J., Belleannée G., Lapuyade B., Terrebonne E., Vendrely V., Laurent C., Sa-Cunha A. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur. J. Radiol. 2013; 82 (4): 589–593. https://doi.org/10.1016/j.ejrad.2012.12.002

11. Macedo F.I., Ryon E., Maithel S.K., Lee R.M., Kooby D.A., Fields R.C., Hawkins W.G., Williams G., Maduekwe U., Kim H.J., Ahmad S.A., Patel S.H., Abbott D.E., Schwartz P., Weber S.M., Scoggins C.R., Martin R.C., Dudeja V., Franceschi D., Livingstone A.S., Merchant N.B. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nabpaclitaxel chemotherapy in resected pancreatic cancer. Ann. Surg. 2019; 270 (3): 400–413. https://doi.org/10.1097/SLA.0000000000003468

12. Sivapalan L., Kocher H.M., Ross-Adams H., Chelala C. Molecular profiling of ctDNA in pancreatic cancer: opportunities and challenges for clinical application. Pancreatology. 2021; 21 (2): 363–378. https://doi.org/10.1016/j.pan.2020.12.017

13. Cloyd J.M., Wang H., Egger M.E., Tzeng C.D., Prakash L.R., Maitra A., Varadhachary G.R., Shroff R., Javle M., Fogelman D., Wolff R.A., Overman M.J., Koay E.J., Das P., Herman J.M., Kim M.P., Vauthey J.N., Aloia T.A., Fleming J.B., Lee J.E., Katz M.H.G. Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma. JAMA Surg. 2017; 152 (11): 1048–1056. https://doi.org/10.1001/jamasurg.2017.2227

14. Cloyd J.M., Ejaz A., Shen C., Dillhoff M., Williams T.M., Noonan A., Pawlik T.M., Tsung A. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. HPB (Oxford). 2020; 22 (11): 1569–1576. https://doi. org/10.1016/j.hpb.2020.01.013

15. Yoon M.S., Lee H.S., Kang C.M., Lee W.J., Keum J., Sung M.J., Kim S.S., Park M.S., Jo J.H., Chung M.J., Park J.Y., Park S.W., Song S.Y., Hwang H.K., Bang S. Response to neoadjuvant therapy and prognosis in patients with resectable pancreatic cancer: a propensity score matching analysis. Gut Liver. 2022; 16 (1): 118–128. https://doi.org/10.5009/gnl20301

16. Zhou Y., Liao S., You J. Pathological complete response after neoadjuvant therapy for pancreatic ductal adenocarcinoma does not equal cure. ANZ J. Surg. 2021; 91 (5): E254–E259. https://doi.org/10.1111/ans.16665

17. Hartford C.M., Dolan M.E. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics. 2007; 8 (9): 1159–1168. https://doi.org/10.2217/14622416.8.9.1159

18. Barrak D., Villano A.M., Villafane-Ferriol N., Stockton L.G., Hill M.V., Deng M., Handorf E.A., Reddy S.S. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. Eur. J. Surg. Oncol. 2022; 48 (6): 1356–1361. https://doi.org/10.1016/j.ejso.2021.12.473